54 results on '"Azzini Am"'
Search Results
2. Interleukin-2-mediated CD4 T-cell activation correlates highly with effective serological and T-cell responses to SARS-CoV-2 vaccination in people living with HIV.
- Author
-
Gupta A, Righi E, Konnova A, Sciammarella C, Spiteri G, Van Averbeke V, Berkell M, Hotterbeekx A, Sartor A, Mirandola M, Malhotra-Kumar S, Azzini AM, Pezzani D, Monaco MGL, Vanham G, Porru S, Tacconelli E, and Kumar-Singh S
- Subjects
- Humans, Male, Middle Aged, Female, Adult, CD4 Lymphocyte Count, Vaccination, Immunoglobulin G blood, Antibodies, Neutralizing blood, Antibodies, Neutralizing immunology, CD4-Positive T-Lymphocytes immunology, HIV Infections immunology, HIV Infections drug therapy, Interleukin-2, COVID-19 immunology, COVID-19 prevention & control, SARS-CoV-2 immunology, Antibodies, Viral blood, Lymphocyte Activation, COVID-19 Vaccines immunology
- Abstract
People living with HIV (PLWH) despite having an appreciable depletion of CD4
+ T-cells show a good severe acute respiratory syndrome coronavirus 2 vaccination response. The underlying mechanism(s) are currently not understood. We studied serological and polyfunctional T-cell responses in PLWH receiving anti-retroviral therapy stratified on CD4+ counts as PLWH-high (CD4 ≥ 500 cells/mm3 ) and PLWH-low (<500 cells/mm3 ). Responses were assessed longitudinally before the first vaccination (T0), 1-month after the first dose (T1), 3-months (T2), and 6-months (T3) after the second dose. Expectedly, both PLWH-high and -low groups developed similar serological responses after T2, which were also non-significantly different from age and vaccination-matched HIV-negative controls at T3. The immunoglobulin G titers were also protective showing a good correlation with angiotensin-converting enzyme 2-neutralizations (R = 0.628, p = 0.005). While surface and intracellular activation analysis showed no significant difference at T3 between PLWH and controls in activated CD4+ CD154+ and CD4+ memory T-cells, spike-specific CD4+ polyfunctional cytokine expression analysis showed that PLWH preferentially express interleukin (IL)-2 (p < 0.001) and controls, interferon-γ (p = 0.017). CD4+ T-cell counts negatively correlated with IL-2-expressing CD4+ T-cells including CD4+ memory T-cells (Spearman ρ: -0.85 and -0.80, respectively; p < 0.001). Our results suggest that the durable serological and CD4+ T-cell responses developing in vaccinated PLWH are associated with IL-2-mediated CD4+ T-cell activation that likely compensates for CD4+ T-cell depletion in PLWH., (© 2024 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC.)- Published
- 2024
- Full Text
- View/download PDF
3. SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T-cell counts in people living with HIV.
- Author
-
Vergori A, Cozzi-Lepri A, Tavelli A, Mazzotta V, Azzini AM, Gagliardini R, Mastrorosa I, Latini A, Pellicanò G, Taramasso L, Ceccherini-Silberstein F, Giannella M, Tacconelli E, Marchetti G, Monforte AD, and Antinori A
- Subjects
- Humans, Middle Aged, Male, Female, CD4 Lymphocyte Count, Vaccination, CD4-Positive T-Lymphocytes immunology, CD4-CD8 Ratio, Viral Load, HIV Infections immunology, HIV Infections virology, HIV Infections drug therapy, COVID-19 immunology, COVID-19 prevention & control, COVID-19 virology, SARS-CoV-2 immunology, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, CD8-Positive T-Lymphocytes immunology
- Abstract
Objectives: To investigate whether SARS-CoV-2 messenger RNA (mRNA) vaccination has an impact on HIV-related viro-immunological parameters., Methods: People with HIV (PWH) in the VAXICONA-ORCHESTRA cohort who received one or more doses of SARS-CoV-2 mRNA vaccine and for whom paired measures of immuno-virological markers (viral load, clusters of differentiation [CD]4, and CD8 count 1 month before and after a vaccine dose [VD]) were available were included. Paired t-test and generalized estimating equation linear regression analyses were used to study changes over ± 1 month around the VD. Subgroup analyses were performed., Results: A total of 510 PWH were enrolled: the median age was 55 years (interquartile range 46-60 years), the CD4 and CD8 count were 489 (287-719) and 790 (59-1104) cells/mm
3 , respectively, and 81% received three VDs. After a median of 28 (3-53) days from VD, CD4 count increased by +15 cells/mm3 (SD ± 129.7, P = 0.001) and CD8 by +12 (±250.5, P = 0.199) and the viral load decreased by -0.11 log10 (±0.88, P = 0.001). Similar results were observed after restricting the analysis to viro-suppressed PWH, with CD4 ≤200/mm3 , more than 6 months of antiretroviral therapy before VD and after excluding previous COVID-19., Conclusions: A small significant increase in CD4 count and a negligible drop in HIV RNA were observed. Our findings are consistent with the hypothesis that SARS-CoV-2 mRNA vaccine can prime CD4 T spike-specific cells, even in the more immuno-compromised PWH., Competing Interests: Declarations of Competing Interest The authors have no competing interests to declare., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
4. Perspectives of European Patient Advocacy Groups on Volunteer Registries and Vaccine Trials: VACCELERATE Survey Study.
- Author
-
Themistocleous S, Argyropoulos CD, Vogazianos P, Shiamakkides G, Noula E, Nearchou A, Yiallouris A, Filippou C, Stewart FA, Koniordou M, Kopsidas I, Askling HH, Vene S, Gagneux-Brunon A, Prellezo JB, Álvarez-Barco E, Salmanton-García J, Leckler J, Macken AJ, Davis RJ, Azzini AM, Armeftis C, Hellemans M, Di Marzo R, Luis C, Olesen OF, Valdenmaiier O, Jakobsen SF, Nauclér P, Launay O, Mallon P, Ochando J, van Damme P, Tacconelli E, Zaoutis T, Cornely OA, and Pana ZD
- Subjects
- Humans, Europe, France, Germany, Clinical Trials as Topic, Patient Advocacy, Vaccines
- Abstract
Background: The VACCELERATE Pan-European Scientific network aims to strengthen the foundation of vaccine trial research across Europe by following the principles of equity, inclusion, and diversity. The VACCELERATE Volunteer Registry network provides access to vaccine trial sites across the European region and supports a sustainable volunteer platform for identifying potential participants for forthcoming vaccine clinical research., Objective: The aim of this study was to approach members of patient advocacy groups (PAGs) across Europe to assess their willingness to register for the VACCELERATE Volunteer Registry and their perspectives related to participating in vaccine trials., Methods: In an effort to understand how to increase recruitment for the VACCELERATE Volunteer Registry, a standardized survey was developed in English and translated into 8 different languages (Dutch, English, French, German, Greek, Italian, Spanish, and Swedish) by the respective National Coordinator team. The online, anonymous survey was circulated, from March 2022 to May 2022, to PAGs across 10 European countries (Belgium, Cyprus, Denmark, France, Germany, Greece, Ireland, Italy, Spain, and Sweden) to share with their members. The questionnaire constituted of multiple choice and open-ended questions evaluating information regarding participants' perceptions on participating in vaccine trials and their willingness to become involved in the VACCELERATE Volunteer Registry., Results: In total, 520 responses were collected and analyzed. The PAG members reported that the principal criteria influencing their decision to participate in clinical trials overall are (1) the risks involved, (2) the benefits that will be gained from their potential participation, and (3) the quality and quantity of information provided regarding the trial. The survey revealed that, out of the 520 respondents, 133 individuals across all age groups were "positive" toward registering in the VACCELERATE Volunteer Registry, with an additional 47 individuals reporting being "very positive." Respondents from Northern European countries were 1.725 (95% CI 1.206-2.468) times more likely to be willing to participate in the VACCELERATE Volunteer Registry than respondents from Southern European countries., Conclusions: Factors discouraging participants from joining vaccine trial registries or clinical trials primarily include concerns of the safety of novel vaccines and a lack of trust in those involved in vaccine development. These outcomes aid in identifying issues and setbacks in present registries, providing the VACCELERATE network with feedback on how to potentially increase participation and enrollment in trials across Europe. Development of European health communication strategies among diverse public communities, especially via PAGs, is the key for increasing patients' willingness to participate in clinical studies., (©Sophia Themistocleous, Christos D Argyropoulos, Paris Vogazianos, George Shiamakkides, Evgenia Noula, Andria Nearchou, Andreas Yiallouris, Charalampos Filippou, Fiona A Stewart, Markela Koniordou, Ioannis Kopsidas, Helena H Askling, Sirkka Vene, Amandine Gagneux-Brunon, Jana Baranda Prellezo, Elena Álvarez-Barco, Jon Salmanton-García, Janina Leckler, Alan J Macken, Ruth Joanna Davis, Anna Maria Azzini, Charis Armeftis, Margot Hellemans, Romina Di Marzo, Catarina Luis, Ole F Olesen, Olena Valdenmaiier, Stine Finne Jakobsen, Pontus Nauclér, Odile Launay, Patrick Mallon, Jordi Ochando, Pierre van Damme, Evelina Tacconelli, Theoklis Zaoutis, Oliver A Cornely, Zoi Dorothea Pana. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 04.04.2024.)
- Published
- 2024
- Full Text
- View/download PDF
5. The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium.
- Author
-
Poulimeneas D, Koniordou M, Kousi D, Merakou C, Kopsidas I, Tsopela GC, Argyropoulos CD, Themistocleous SC, Shiamakkides G, Constantinou M, Alexandrou A, Noula E, Nearchou A, Salmanton-García J, Stewart FA, Heringer S, Albus K, Álvarez-Barco E, Macken A, Di Marzo R, Luis C, Valle-Simón P, Askling HH, Hellemans M, Spivak O, Davis RJ, Azzini AM, Barta I, Součková L, Jancoriene L, Akova M, Mallon PWG, Olesen OF, Frias-Iniesta J, van Damme P, Tóth K, Cohen-Kandli M, Cox RJ, Husa P, Nauclér P, Marques L, Ochando J, Tacconelli E, Zeitlinger M, Cornely OA, Pana ZD, and Zaoutis TE
- Abstract
Underserved and hard-to-reach population groups are under-represented in vaccine trials. Thus, we aimed to identify the challenges of vaccine trial participation of these groups in member countries of the VACCELERATE network. Seventeen National Coordinators (NC), each representing their respective country (15 European countries, Israel, and Turkey), completed an online survey. From 15 eligible groups, those that were more frequently declared underserved/hard-to-reach in vaccine research were ethnic minorities (76.5%), persons experiencing homelessness (70.6%), illegal workers and refugees (64.7%, each). When prioritization for education on vaccine trials was considered, ethnic groups, migrants, and immigrants (5/17, 29.4%) were the groups most frequently identified by the NC as top targets. The most prominent barriers in vaccine trial participation affecting all groups were low levels of health literacy, reluctance to participate in trials due to engagement level, and low levels of trust in vaccines/vaccinations. This study highlighted population groups considered underserved/hard-to-reach in countries contained within the European region, and the respective barriers these groups face when participating in clinical studies. Our findings aid with the design of tailored interventions (within-and across-countries of the European region) and with the development of strategies to overcome major barriers in phase 2 and phase 3 vaccine trial participation.
- Published
- 2023
- Full Text
- View/download PDF
6. SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 Ratio.
- Author
-
Vergori A, Tavelli A, Matusali G, Azzini AM, Augello M, Mazzotta V, Pellicanò GF, Costantini A, Cascio A, De Vito A, Marconi L, Righi E, Sartor A, Pinnetti C, Maggi F, Bai F, Lanini S, Piconi S, Levy Hara G, Marchetti G, Giannella M, Tacconelli E, d'Arminio Monforte A, Antinori A, Cozzi-Lepri A, and On Behalf Of The Vax-Icona-Orchestra Study
- Abstract
Background: Our aim was to estimate the rates of not achieving a robust/above-average humoral response to the COVID-19 mRNA vaccine in people living with HIV (PLWH) who received ≥2 doses and to investigate the role of the CD4 and CD4/CD8 ratio in predicting the humoral response., Methods: We evaluated the humoral anti-SARS-CoV-2 response 1-month after the second and third doses of COVID-19 mRNA vaccine as a proportion of not achieving a robust/above-average response using two criteria: (i) a humoral threshold identified as a correlate of protection against SARS-CoV-2 (<90% vaccine efficacy): anti-RBD < 775 BAU/mL or anti-S < 298 BAU/mL, (ii) threshold of binding antibodies equivalent to average neutralization activity from the levels of binding (nAb titer < 1:40): anti-RBD < 870 BAU/mL or anti-S < 1591 BAU/mL. PLWH were stratified according to the CD4 count and CD4/CD8 ratio at first dose. Logistic regression was used to compare the probability of not achieving robust/above-average responses. A mixed linear model was used to estimate the mean anti-RBD titer at various time points across the exposure groups., Results: a total of 1176 PLWH were included. The proportions of participants failing to achieve a robust/above-average response were significantly higher in participants with a lower CD4 and CD4/CD8 ratio, specifically, a clearer gradient was observed for the CD4 count. The CD4 count was a better predictor of the humoral response of the primary cycle than ratio. The third dose was pivotal in achieving a robust/above-average humoral response, at least for PLWH with CD4 > 200 cells/mm
3 and a ratio > 0.6., Conclusions: A robust humoral response after a booster dose has not been reached by 50% of PLWH with CD4 < 200 cells mm3 . In the absence of a validated correlate of protections in the Omicron era, the CD4 count remains the most solid marker to guide vaccination campaigns in PLWH.- Published
- 2023
- Full Text
- View/download PDF
7. How European Research Projects Can Support Vaccination Strategies: The Case of the ORCHESTRA Project for SARS-CoV-2.
- Author
-
Azzini AM, Canziani LM, Davis RJ, Mirandola M, Hoelscher M, Meyer L, Laouénan C, Giannella M, Rodríguez-Baño J, Boffetta P, Mates D, Malhotra-Kumar S, Scipione G, Stellmach C, Rinaldi E, Hasenauer J, and Tacconelli E
- Abstract
ORCHESTRA ("Connecting European Cohorts to Increase Common and Effective Response To SARS-CoV-2 Pandemic") is an EU-funded project which aims to help rapidly advance the knowledge related to the prevention of the SARS-CoV-2 infection and the management of COVID-19 and its long-term sequelae. Here, we describe the early results of this project, focusing on the strengths of multiple, international, historical and prospective cohort studies and highlighting those results which are of potential relevance for vaccination strategies, such as the necessity of a vaccine booster dose after a primary vaccination course in hematologic cancer patients and in solid organ transplant recipients to elicit a higher antibody titer, and the protective effect of vaccination on severe COVID-19 clinical manifestation and on the emergence of post-COVID-19 conditions. Valuable data regarding epidemiological variations, risk factors of SARS-CoV-2 infection and its sequelae, and vaccination efficacy in different subpopulations can support further defining public health vaccination policies.
- Published
- 2023
- Full Text
- View/download PDF
8. VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe.
- Author
-
Salmanton-García J, Wipfler P, Valle-Simón P, Merakou C, Kopsidas I, Bethe U, Steinbach A, Spivak O, Součková L, Mendonça MA, Koniordou M, Hellemans M, Frías-Iniesta J, Davis RJ, Barta I, Azzini AM, Askling HH, Argyropoulos CD, Álvarez-Barco E, Akova M, Bonten MMJ, Cohen-Kandli M, Cox RJ, Flisiak R, Husa P, Jancoriene L, Koscalova A, Launay O, Lundgren J, Mallon P, Marques L, Nauclér P, Ochando J, Pana ZD, Tacconelli E, Tóth K, Trelle S, van Damme P, Zaoutis TE, Zeitlinger M, Albus K, Stewart FA, Hofstraat SHI, Bruijning-Verhagen P, and Cornely OA
- Subjects
- Adult, Child, Humans, SARS-CoV-2, Europe, COVID-19, Vaccines, Orthomyxoviridae
- Abstract
Background: The inconsistent European vaccine trial landscape rendered the continent of limited interest for vaccine developers. The VACCELERATE consortium created a network of capable clinical trial sites throughout Europe. VACCELERATE identifies and provides access to state-of-the-art vaccine trial sites to accelerate clinical development of vaccines., Methods: Login details for the VACCELERATE Site Network (vaccelerate.eu/site-network/) questionnaire can be obtained after sending an email to. Interested sites provide basic information, such as contact details, affiliation with infectious disease networks, main area of expertise, previous vaccine trial experience, site infrastructure and preferred vaccine trial settings. In addition, sites can recommend other clinical researchers for registration in the network. If directly requested by a sponsor or sponsor representative, the VACCELERATE Site Network pre-selects vaccine trial sites and shares basic study characteristics provided by the sponsor. Interested sites provide feedback with short surveys and feasibility questionnaires developed by VACCELERATE and are connected with the sponsor to initiate the site selection process., Results: As of April 2023, 481 sites from 39 European countries have registered in the VACCELERATE Site Network. Of these, 137 (28.5 %) sites have previous experience conducting phase I trials, 259 (53.8 %) with phase II, 340 (70.7 %) with phase III, and 205 (42.6 %) with phase IV trials, respectively. Infectious diseases were reported as main area of expertise by 274 sites (57.0 %), followed by any kind of immunosuppression by 141 (29.3 %) sites. Numbers are super additive as sites may report clinical trial experience in several indications. Two hundred and thirty-one (47.0 %) sites have the expertise and capacity to enrol paediatric populations and 391 (79.6 %) adult populations. Since its launch in October 2020, the VACCELERATE Site Network has been used 21 times for academic and industry trials, mostly interventional studies, focusing on different pathogens such as fungi, monkeypox virus, Orthomyxoviridae/influenza viruses, SARS-CoV-2, or Streptococcus pneumoniae/pneumococcus., Conclusions: The VACCELERATE Site Network enables a constantly updated Europe-wide mapping of experienced clinical sites interested in executing vaccine trials. The network is already in use as a rapid-turnaround single contact point for the identification of vaccine trials sites in Europe., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: VACCELERATE Consortium reports financial support was provided by European Union. VACCELERATE Consortium reports financial support was provided by Federal Ministry of Education and Research Bonn Office., (Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
9. Risk factors for colonization with multidrug-resistant Gram-negative bacteria and Clostridioides difficile in Long Term Care Facilities (LTCFs) residents: the evidence from 27 facilities in a high endemic setting.
- Author
-
Azzini AM, Be G, Naso L, Lambertenghi L, Salerno ND, Coledan I, Bazaj A, Mirandola M, Miotti J, Mazzaferri F, Accordini S, Lo Cascio G, and Tacconelli E
- Subjects
- Humans, Clostridioides, Long-Term Care, Escherichia coli genetics, Drug Resistance, Multiple, Bacterial, Risk Factors, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Carbapenems therapeutic use, Cephalosporins pharmacology, Cephalosporins therapeutic use, Gram-Negative Bacteria genetics, Prevalence, Clostridioides difficile genetics, Gram-Negative Bacterial Infections microbiology
- Abstract
Introduction: Residency in LTCFs increases the likelihood of colonization with multidrug resistant Gram-negative bacteria (MDR-GNB). We assessed the prevalence and risk factors for enteric colonization by III-generation cephalosporins-resistant and carbapenem-resistant (CR) GNB in a large group of LTCFs in a high endemic setting. We also assessed the prevalence and risk factors for C. difficile colonization., Methods: A point prevalence survey with rectal screening (RS) was conducted in 27 LTCFs in north Italy. Epidemiological and clinical variables on the survey day, history of hospitalization and surgery within one year, and antibiotics within three months, were collected. The presence of III-generation cephalosporin resistant and CR GNB was assessed using a selective culture on chromogenic medium and PCR for carbapenemase detection. The presence of C. difficile was assessed using ELISA for GDH and RT-PCR to identify toxigenic strains. Multi-variable analyses were performed using two-level logistic regression models., Results: In the study period 1947 RSs were performed. The prevalence of colonization by at least one GNB resistant to III-generation cephalosporin was 51% ( E. coli 65%, K. pneumoniae 14% of isolates). The prevalence of colonization by CR GNB was 6%. 6% of all isolates (1150 strains) resulted in a carbapenem-resistant K. pneumoniae , and 3% in a carbapenem-resistant E. coli . KPC was the most frequent carbapenemase (73%) identified by PCR, followed by VIM (23%). The prevalence of colonization by C. difficile was 11.7%. The presence of a medical device (OR 2.67) and previous antibiotic use (OR 1.48) were significantly associated with III-generation cephalosporin resistant GNB colonization. The presence of a medical device (OR 2.67) and previous hospitalization (OR 1.80) were significantly associated with CR GNB. The presence of a medical device (OR 2.30) was significantly associated with C. difficile colonization. Main previously used antibiotic classes were fluoroquinolones (32% of previously treated subjects), III-generation cephalosporins (21%), and penicillins (19%)., Conclusion: Antimicrobial stewardship in LTCFs is a critical issue, being previous antibiotic treatment a risk factor for colonization by MDR-GNB. The prevalence of colonization by III-generation cephalosporin and CR GNB among LTCF residents also underlines the importance to adhere to hand hygiene indications, infection prevention and control measures, and environmental hygiene protocols, more achievable than rigorous contact precautions in this type of social setting., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Azzini, Be, Naso, Lambertenghi, Salerno, Coledan, Bazaj, Mirandola, Miotti, Mazzaferri, Accordini, Lo Cascio and Tacconelli.)
- Published
- 2023
- Full Text
- View/download PDF
10. Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCELERATE Toolkit.
- Author
-
Argyropoulos CD, Leckler J, Salmanton-García J, Constantinou M, Alexandrou A, Themistocleous S, Noula E, Shiamakkides G, Nearchou A, Stewart FA, Albus K, Koniordou M, Kopsidas I, Spivak O, Hellemans M, Hendrickx G, Davis RJ, Azzini AM, Simon PV, Carcas-Sansuan AJ, Askling HH, Vene S, Prellezo JB, Álvarez-Barco E, Macken AJ, Di Marzo R, Luís C, Olesen OF, Frias Iniesta JA, Barta I, Tóth K, Akova M, Bonten MMJ, Cohen-Kandli M, Cox RJ, Součková L, Husa P, Jancoriene L, Launay O, Lundgren J, Mallon P, Armeftis C, Marques L, Naucler P, Ochando J, Tacconelli E, van Damme P, Zaoutis T, Hofstraat S, Bruijning-Verhagen P, Zeitlinger M, Cornely OA, and Pana ZD
- Subjects
- Child, Adolescent, Humans, Aged, COVID-19 Vaccines, Europe, COVID-19 prevention & control, Health Communication, Vaccines
- Abstract
Background: The pan-European VACCELERATE network aims to implement the first transnational harmonized and sustainable vaccine trial Volunteer Registry, being a single entry point for potential volunteers of large-scale vaccine trials across Europe. This work exhibits a set of harmonized vaccine trial-related educational and promotional tools for the general public, designed and disseminated by the pan-European VACCELERATE network., Objective: This study primarily aimed to design and develop a standard toolkit to increase positive attitudes and access to trustworthy information for better access and increased recruitment to vaccine trials for the public. More specifically, the produced tools are focused on inclusiveness and equity, and are targeting different population groups, including underserved ones, as potential volunteers for the VACCELERATE Volunteer Registry (older individuals, migrants, children, and adolescents). The promotional and educational material is aligned with the main objectives of the Volunteer Registry to increase public literacy and awareness regarding vaccine-related clinical research or trials and trial participation, including informed consent and legal issues, side effects, and frequently asked questions regarding vaccine trial design., Methods: Tools were developed per the aims and principles of the VACCELERATE project, focusing on trial inclusiveness and equity, and are adjusted to local country-wise requirements to improve public health communication. The produced tools are selected based on the cognitive theory, inclusiveness, and equity of differently aged and underrepresented groups, and standardized material from several official trustworthy sources (eg, COVID-19 Vaccines Global Access; the European Centre for Disease Prevention and Control; the European Patients' Academy on Therapeutic Innovation; Gavi, the Vaccine Alliance; and the World Health Organization). A team of multidisciplinary specialists (infectious diseases, vaccine research, medicine, and education) edited and reviewed the subtitles and scripts of the educational videos, extended brochures, interactive cards, and puzzles. Graphic designers selected the color palette, audio settings, and dubbing for the video story-tales and implemented QR codes., Results: This study presents the first set of harmonized promotional and educational materials and tools (ie, educational cards, educational and promotional videos, extended brochures, flyers, posters, and puzzles) for vaccine clinical research (eg, COVID-19 vaccines). These tools inform the public about possible benefits and disadvantages of trial participation and build confidence among participants about the safety and efficacy of COVID-19 vaccines and the health care system. This material has been translated into several languages and is intended to be freely and easily accessible to facilitate dissemination among VACCELERATE network participant countries and the European and global scientific, industrial, and public community., Conclusions: The produced material could help fill knowledge gaps of health care personnel, providing the appropriate future patient education for vaccine trials, and tackling vaccine hesitancy and parents' concerns for potential participation of children in vaccine trials., (©Christos D Argyropoulos, Janina Leckler, Jon Salmanton-García, Marinos Constantinou, Alexandra Alexandrou, Sophia Themistocleous, Evgenia Noula, George Shiamakkides, Andria Nearchou, Fiona A Stewart, Kerstin Albus, Markela Koniordou, Ioannis Kopsidas, Orly Spivak, Margot Hellemans, Greet Hendrickx, Ruth Joanna Davis, Anna Maria Azzini, Paula Valle Simon, Antonio Javier Carcas-Sansuan, Helena Hervius Askling, Sirkka Vene, Jana Baranda Prellezo, Elena Álvarez-Barco, Alan J Macken, Romina Di Marzo, Catarina Luís, Ole F Olesen, Jesus A Frias Iniesta, Imre Barta, Krisztina Tóth, Murat Akova, Marc M J Bonten, Miriam Cohen-Kandli, Rebecca Jane Cox, Lenka Součková, Petr Husa, Ligita Jancoriene, Odile Launay, Jens Lundgren, Patrick Mallon, Charis Armeftis, Laura Marques, Pontus Naucler, Jordi Ochando, Evelina Tacconelli, Pierre van Damme, Theoklis Zaoutis, Sanne Hofstraat, Patricia Bruijning-Verhagen, Markus Zeitlinger, Oliver A Cornely, Zoi Dorothea Pana. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 03.04.2023.)
- Published
- 2023
- Full Text
- View/download PDF
11. The multi-drug resistant organisms infections decrease during the antimicrobial stewardship era in cirrhotic patients: An Italian cohort study.
- Author
-
Dalbeni A, Mantovani A, Zoncapè M, Cattazzo F, Bevilacqua M, De Marco L, Paon V, Ieluzzi D, Azzini AM, Carrara E, Tacconelli E, and Sacerdoti D
- Subjects
- Humans, Cohort Studies, Enterococcus, Gram-Negative Bacteria, Liver Cirrhosis complications, Liver Cirrhosis drug therapy, Drug Resistance, Multiple, Bacterial, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents pharmacology, Antimicrobial Stewardship, Bacterial Infections complications, Bacterial Infections drug therapy, Bacterial Infections epidemiology
- Abstract
Background and Purpose: Bacterial infections represent a major cause of morbidity and mortality in cirrhotic patients. Our aim was to assess the incidence of bacterial infections, in particular due to multidrug-resistant organisms (MDROs) before and after the introduction of the antimicrobial stewardship program, "Stewardship Antimicrobial in VErona" (SAVE). In addition, we also analysed the liver complications and the crude mortality during the whole follow up., Methods: We analysed 229 cirrhotic subjects without previous hospitalization for infections enrolled at the University Verona Hospital from 2017 to 2019 and followed up until December 2021 (mean follow-up 42.7 months)., Results: 101 infections were recorded and 31.7% were recurrent. The most frequent were sepsis (24.7%), pneumonia (19.8%), spontaneous bacterial peritonitis (17.8%). 14.9% of infections were sustained by MDROs. Liver complications occurred more frequently in infected patients, and in case of MDROs infections with a significantly higher MELD and Child-Pugh score. In Cox regression analysis, mortality was associated with age, diabetes and bacterial infections episodes (OR 3.30, CI 95%: (1.63-6.70). Despite an increase in total infections over the past three years, a decrease in the incidence rate in MDROs infections was documented concurrently with the introduction of SAVE (IRD 28.6; 95% CI: 4.6-52.5, p = 0.02)., Conclusions: Our study confirms the burden of bacterial infections in cirrhotic patients, especially MDROs, and the strong interconnection with liver complications. The introduction of SAVE decreased MDROs infections. Cirrhotic patients require a closer clinical surveillance to identify colonized patients and avoid the horizontal spread of MDROs in this setting., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2023 Dalbeni et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2023
- Full Text
- View/download PDF
12. Predictors of clinical evolution of SARS-CoV-2 infection in hematological patients: A systematic review and meta-analysis.
- Author
-
Carrara E, Razzaboni E, Azzini AM, De Rui ME, Pinho Guedes MN, Gorska A, Giannella M, Bussini L, Bartoletti M, Arbizzani F, Palacios-Baena ZR, Caponcello G, Maldonado N, Rodríguez-Baño J, Visco C, Krampera M, and Tacconelli E
- Subjects
- Adult, Humans, Male, SARS-CoV-2, Retrospective Studies, Disease Progression, COVID-19, Hypertension, Neoplasms
- Abstract
Main aim of this systematic review is to quantify the risk and identify predictors of clinical evolution of SARS-CoV-2 in hematological patients compared to different control populations. Two independent reviewers screened the literature assessing clinical outcomes of SARS-CoV-2 infection in adult patients with active hematological malignancies published up to June 2021. Primary outcome was COVID-19 related mortality, secondary outcomes were hospital and intensive-care admission, mechanical ventilation (MV), and thromboembolic events. Variables related to study setting, baseline patients' demographic, comorbidities, underlying hematological disease, ongoing chemotherapy, COVID-19 presentation, and treatments were extracted. A total of 67 studies including 10,061 hematological patients and 111,143 controls were included. Most of the studies were retrospective cohorts (51 studies, 76%) and only 19 (13%) provided data for a control group. A significant increased risk of clinical progression in the hematological population compared to the controls was found in terms of COVID-19 related mortality (OR, 2.12; 95% CI, 1.77-2.54), hospitalization (OR, 1.98; 95% CI, 1.15-3.43), intensive-care admission (OR, 1.77; 95% CI, 1.38-2.26), and MV (OR, 2.17; 95% CI, 1.71-2.75). The risk remained significantly higher in the subgroup analysis comparing hematological patients versus solid cancer. Meta-regression analysis of uncontrolled studies showed that older age, male sex, and hypertension were significantly related to worse clinical outcomes of COVID-19 in hematological population. Older age and hypertension were found to be associated also to thromboembolic events. In conclusion, hematological patients have a higher risk of COVID-19 clinical progression compared to both the general population and to patients with solid cancer., (© 2022 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
13. High Plasma Levels of Activated Factor VII-Antithrombin Complex Point to Increased Tissue Factor Expression in Patients with SARS-CoV-2 Pneumonia: A Potential Link with COVID-19 Prothrombotic Diathesis.
- Author
-
Martinelli N, Rigoni AM, De Marchi S, Osti N, Donini M, Montagnana M, Castagna A, Pattini P, Udali S, De Franceschi L, Tinazzi E, Mazzi F, Moruzzi S, Argentino G, Delfino L, Sartori G, Azzini AM, Tacconelli E, Van Dreden P, Lippi G, Girelli D, Olivieri O, Friso S, and Pizzolo F
- Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causal agent of coronavirus disease 2019 (COVID-19), in which coagulation abnormalities and endothelial dysfunction play a key pathogenic role. Tissue factor (TF) expression is triggered by endothelial dysfunction. Activated factor VII-antithrombin (FVIIa-AT) complex reflects indirectly FVIIa-TF interaction and has been proposed as a potential biomarker of prothrombotic diathesis. FVIIa-AT plasma concentration was measured in 40 patients (30 males and 10 females; 64.8 ± 12.3 years) admitted with SARS-CoV-2 pneumonia during the first pandemic wave in Italy. Two sex- and age-matched cohorts without COVID-19, with or without signs of systemic inflammation, were used to compare FVIIa-AT data. The FVIIa-AT plasma levels in COVID-19 patients were higher than those in non-COVID-19 subjects, either with or without inflammation, while no difference was observed among non-COVID-19 subjects. The association between COVID-19 and FVIIa-AT levels remained significant after adjustment for sex, age, C-reactive protein, renal function, fibrinogen, prothrombin time and activated partial thromboplastin time. Our results indicate that SARS-CoV-2 infection, at least during the first pandemic wave, was characterized by high FVIIa-AT levels, which may suggest an enhanced FVIIa-TF interaction in COVID-19, potentially consistent with SARS-CoV-2-induced endotheliopathy.
- Published
- 2022
- Full Text
- View/download PDF
14. How to 'SAVE' antibiotics: effectiveness and sustainability of a new model of antibiotic stewardship intervention in the internal medicine area.
- Author
-
Carrara E, Sibani M, Barbato L, Mazzaferri F, Salerno ND, Conti M, Azzini AM, Dalbeni A, Pellizzari L, Fontana G, Di Francesco V, Bissoli L, Del Monte L, Zamboni M, Olivieri O, Minuz P, Maccacaro L, Ghirlanda G, and Tacconelli E
- Subjects
- Humans, Anti-Bacterial Agents therapeutic use, Carbapenems therapeutic use, Fluoroquinolones therapeutic use, Internal Medicine, Antimicrobial Stewardship, Cross Infection drug therapy
- Abstract
Background: Antibiotic stewardship (AS) is a cornerstone of the fight against antimicrobial resistance; however, evidence on the best practice to improve antibiotic prescription in various hospital settings is still scarce. This study aimed to measure the efficacy of a non-restrictive AS intervention in the internal medicine area of a tertiary-care hospital across a 3-year period., Methods: The intervention comprised a 3-month 'intensive phase' based on education and guidelines provision, followed by 9 months of audits and feedback activities. The primary outcome was the overall antibiotic consumption measured as days of therapy (DOTs) and defined daily doses (DDDs). Secondary outcomes were carbapenem and fluoroquinolone consumption, all-cause in-hospital mortality, length of stay, incidence of Clostridioides difficile and carbapenem-resistant Enterobacterales bloodstream infections (CRE-BSIs). All outcomes were measured in the intervention wards comparing the pre-phase with the post-phase using an interrupted time-series model., Results: A total of 145 337 patient days (PDs) and 14 159 admissions were included in the analysis. The intervention was associated with reduced DOTs*1000PDs (-162.2/P = 0.005) and DDDs*1000PDs (-183.6/P ≤ 0.001). A sustained decrease in ward-related antibiotic consumption was also detected during the post-intervention phase and in the carbapenem/fluoroquinolone classes. The intervention was associated with an immediate reduction in length of stay (-1.72 days/P < 0.001) and all-cause mortality (-3.71 deaths*100 admissions/P = 0.002), with a decreasing trend over time. Rates of Clostridioides difficile infections and CRE-BSIs were not significantly impacted by the intervention., Conclusions: The AS intervention was effective and safe in decreasing antibiotic consumption and length of stay in the internal medicine area. Enabling prescribers to judicious use of antimicrobials through active participation in AS initiatives is key to reach sustained results over time., (Copyright © 2022 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
15. Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis.
- Author
-
Gatti M, Rinaldi M, Bussini L, Bonazzetti C, Pascale R, Pasquini Z, Faní F, Pinho Guedes MN, Azzini AM, Carrara E, Palacios-Baena ZR, Caponcello G, Reyna-Villasmil E, Tacconelli E, Rodríguez-Baño J, Viale P, and Giannella M
- Subjects
- Humans, Prospective Studies, Retrospective Studies, Transplant Recipients, COVID-19 epidemiology, Organ Transplantation adverse effects
- Abstract
Background: A significant increased risk of complications and mortality in immunocompromised patients affected by COVID-19 has been described. However, the impact of COVID-19 in solid organ transplant (SOT) recipients is an issue still under debate, due to conflicting evidence that has emerged from different observational studies., Objectives: We performed a systematic review with a meta-analysis to assess the clinical outcome in SOT recipients with COVID-19 compared with the general population., Data Sources: PubMed-MEDLINE and Scopus were independently searched until 13 October 2021., Study Eligibility Criteria: Prospective or retrospective observational studies comparing clinical outcome in SOT recipients versus general populations affected by COVID-19 were included. The primary endpoint was 30-day mortality., Participants: Participants were patients with confirmed COVID-19., Interventions: Interventions reviewed were SOTs., Methods: The quality of the included studies was independently assessed with the Risk of Bias in Non-randomized Studies of Interventions tool for observational studies. The meta-analysis was performed by pooling ORs retrieved from studies providing adjustment for confounders using a random-effects model with the inverse variance method. Multiple subgroups and sensitivity analyses were conducted to investigate the source of heterogeneity., Results: A total of 3501 articles were screened, and 31 observational studies (N = 590 375; 5759 SOT recipients vs. 584 616 general population) were included in the meta-analyses. No difference in 30-day mortality rate was found in the primary analysis, including studies providing adjustment for confounders (N = 17; 3752 SOT recipients vs. 159 745 general population; OR: 1.13; 95% CI, 0.94-1.35; I
2 = 33.9%). No evidence of publication bias was reported. A higher risk of intensive care unit admission (OR: 1.56; 95% CI, 1.03-2.63) and occurrence of acute kidney injury (OR: 2.50; 95% CI, 1.81-3.45) was found in SOT recipients., Conclusions: No increased risk in mortality was found in SOT recipients affected by COVID-19 compared with the general population when adjusted for demographic and clinical features and COVID-19 severity., (Copyright © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
16. The clinical and economic impact of surgical site infections after distal pancreatectomy.
- Author
-
De Pastena M, Paiella S, Fontana M, Filippini C, Addari L, Giorgi A, Canton S, Zanusso G, Azzini AM, Bassi C, Tacconelli E, and Salvia R
- Subjects
- Adult, Humans, Length of Stay, Operative Time, Postoperative Complications epidemiology, Postoperative Complications etiology, Prospective Studies, Retrospective Studies, Surgical Wound Infection diagnosis, Surgical Wound Infection epidemiology, Surgical Wound Infection etiology, Laparoscopy, Pancreatectomy adverse effects
- Abstract
Background: The present study aimed to evaluate surgical site infections' clinical and economic impact after distal pancreatectomy., Methods: The study was a prospective, monocentric, observational study, including all adult patients who underwent distal pancreatectomy. According to the American Centers for Disease Control and Prevention definition, the surgical site infection assessment was prospectively performed by trained personnel. The Accordion Severity Grading System was used to evaluate the clinical burden of surgical site infection. The hospitalization's total costs were calculated using the hospital expenditure report, excluding the intraoperative costs., Results: During the study period, 414 distal pancreatectomies were performed. The overall incidence of surgical site infection was 26% (106 patients). Surgical site infections were associated with a higher body mass index (P = .022, odds ratio 1.2), positive preoperative rectal swab for multidrug resistant bacteria (P = .010, odds ratio 4.2), and increased operative time (P = .037, odds ratio 1.1). Using the Accordion Severity Grading System, surgical site infections contributed significantly to the total clinical burden (25.5%) and prolonged hospitalization (P < .001). Furthermore, surgical site infection doubled the costs (12.915 vs 6.888 euros, P < .001)., Conclusion: Surgical site infection has a high clinical burden, negatively impacting the postoperative course. The costs and length of stay proportionally increased with the surgical site infection severity, doubling the hospitalization expenses., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
17. Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study.
- Author
-
Bassetti M, Vena A, Giacobbe DR, Trucchi C, Ansaldi F, Antonelli M, Adamkova V, Alicino C, Almyroudi MP, Atchade E, Azzini AM, Brugnaro P, Carannante N, Peghin M, Berruti M, Carnelutti A, Castaldo N, Corcione S, Cortegiani A, Dimopoulos G, Dubler S, García-Garmendia JL, Girardis M, Cornely OA, Ianniruberto S, Kullberg BJ, Lagrou K, Lebihan C, Luzzati R, Malbrain M, Merelli M, Marques AJ, Martin-Loeches I, Mesini A, Paiva JA, Raineri SM, Rautemaa-Richardson R, Schouten J, Spapen H, Tasioudis P, Timsit JF, Tisa V, Tumbarello M, Van den Berg CHSB, Veber B, Venditti M, Voiriot G, Wauters J, Zappella N, and Montravers P
- Abstract
Introduction: Intra-abdominal infections represent the second most frequently acquired infection in the intensive care unit (ICU), with mortality rates ranging from 20% to 50%. Candida spp. may be responsible for up to 10-30% of cases. This study assesses risk factors for development of intra-abdominal candidiasis (IAC) among patients admitted to ICU., Methods: We performed a case-control study in 26 European ICUs during the period January 2015-December 2016. Patients at least 18 years old who developed an episode of microbiologically documented IAC during their stay in the ICU (at least 48 h after admission) served as the case cohort. The control group consisted of adult patients who did not develop episodes of IAC during ICU admission. Matching was performed at a ratio of 1:1 according to time at risk (i.e. controls had to have at least the same length of ICU stay as their matched cases prior to IAC onset), ICU ward and period of study., Results: During the study period, 101 case patients with a diagnosis of IAC were included in the study. On univariate analysis, severe hepatic failure, prior receipt of antibiotics, prior receipt of parenteral nutrition, abdominal drain, prior bacterial infection, anastomotic leakage, recurrent gastrointestinal perforation, prior receipt of antifungal drugs and higher median number of abdominal surgical interventions were associated with IAC development. On multivariate analysis, recurrent gastrointestinal perforation (OR 13.90; 95% CI 2.65-72.82, p = 0.002), anastomotic leakage (OR 6.61; 95% CI 1.98-21.99, p = 0.002), abdominal drain (OR 6.58; 95% CI 1.73-25.06, p = 0.006), prior receipt of antifungal drugs (OR 4.26; 95% CI 1.04-17.46, p = 0.04) or antibiotics (OR 3.78; 95% CI 1.32-10.52, p = 0.01) were independently associated with IAC., Conclusions: Gastrointestinal perforation, anastomotic leakage, abdominal drain and prior receipt of antifungals or antibiotics may help to identify critically ill patients with higher probability of developing IAC. Prospective studies are needed to identify which patients will benefit from early antifungal treatment., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
18. Resistome and Virulome of Multi-Drug Resistant E. coli ST131 Isolated from Residents of Long-Term Care Facilities in the Northern Italian Region.
- Author
-
Cherubini S, Perilli M, Azzini AM, Tacconelli E, Maccacaro L, Bazaj A, Naso L, Amicosante G, Ltcf-Veneto Working Group, Lo Cascio G, and Piccirilli A
- Abstract
Long-term care facilities (LTCFs) are important reservoirs of antimicrobial-resistant (AMR) bacteria which colonize patients transferred from the hospital, or they may emerge in the facility as a result of mutation or gene transfer. In the present study, we characterized, from a molecular point of view, 43 E. coli strains collected from residents of LTCFs in Northern Italy. The most common lineage found was ST131, followed by sporadic presence of ST12, ST69, ST48, ST95, ST410 and ST1193. All strains were incubators of several virulence factors, with iss , sat , iha and senB being found in 84%, 72%, 63% and 51% of E. coli , respectively. Thirty of the ST131 analyzed were of the O25b:H4 serotype and H30 subclone. The ST131 isolates were found to be mainly associated with IncF plasmids, CTX-M-1, CTX-M-3, CTX-M-15, CTX-M-27 and gyrA/parC/parE mutations. Metallo-β-lactamases were not found in ST131, whereas KPC-3 carbapenemase was found only in two ST131 and one ST1193. In conclusion, we confirmed the spread of extended-spectrum β-lactamase genes in E. coli ST131 isolated from colonized residents living inside LTCFs. The ST131 represents an incubator of fluoroquinolones, aminoglycosides and other antibiotic resistance genes in addition to different virulence factors.
- Published
- 2022
- Full Text
- View/download PDF
19. Predicting candidemia in internal medicine departments: are we chasing the Holy Grail?
- Author
-
Pieralli F, Azzini AM, Concia E, Lo Cascio G, Tedesco A, Benedetti V, Piredda S, Giusti M, Santini C, Zagarrì E, Fontanella A, and Manfellotto D
- Subjects
- Humans, Internal Medicine, Risk Factors, Candidemia diagnosis, Candidemia drug therapy
- Published
- 2021
- Full Text
- View/download PDF
20. Whole-Genome Sequencing (WGS) of Carbapenem-Resistant K. pneumoniae Isolated in Long-Term Care Facilities in the Northern Italian Region.
- Author
-
Piccirilli A, Cherubini S, Azzini AM, Tacconelli E, Lo Cascio G, Maccacaro L, Bazaj A, Naso L, Amicosante G, Ltcf-Veneto Working Group, and Perilli M
- Abstract
K. pneumoniae (KPN) is one of the widest spread bacteria in which combined resistance to several antimicrobial groups is frequent. The most common β-lactamases found in K. pneumoniae are class A carbapenemases, both chromosomal-encoded (i.e., NMCA, IMI-1) and plasmid-encoded (i.e., GES-enzymes, IMI-2), VIM, IMP, NDM, OXA-48, and extended-spectrum β-lactamases (ESBLs) such as CTX-M enzymes. In the present study, a total of 68 carbapenem-resistant KPN were collected from twelve long-term care facilities (LTCFs) in the Northern Italian region. The whole-genome sequencing (WGS) of each KPN strain was determined using a MiSeq Illumina sequencing platform and analysed by a bacterial analysis pipeline (BAP) tool. The WGS analysis showed the prevalence of ST307, ST512, and ST37 as major lineages diffused among the twelve LTCFs. The other lineages found were: ST11, ST16, ST35, ST253, ST273, ST321, ST416, ST1519, ST2623, and ST3227. The bla
KPC- 2 , blaKPC- 3 , blaKPC- 9 , blaSHV- 11 , blaSHV- 28 , blaCTX-M- 15 , blaOXA- 1 , blaOXA- 9 , blaOXA- 23 , qnrS1 , qnrB19 , qnrB66 , aac(6')-Ib-cr , and fosA were the resistance genes widespread in most LTCFs. In this study, we demonstrated the spreading of thirteen KPN lineages among the LTCFs. Additionally, KPC carbapenemases are the most widespread β-lactamase.- Published
- 2021
- Full Text
- View/download PDF
21. Antibiotic Prophylaxis with Piperacillin-Tazobactam Reduces Post-Operative Infectious Complication after Pancreatic Surgery: An Interventional, Non-Randomized Study.
- Author
-
De Pastena M, Paiella S, Azzini AM, Zaffagnini A, Scarlini L, Montagnini G, Maruccio M, Filippini C, Romeo F, Mazzariol A, Cascio GL, Bazaj A, Secchettin E, Bassi C, and Salvia R
- Subjects
- Anti-Bacterial Agents therapeutic use, Humans, Penicillanic Acid therapeutic use, Piperacillin therapeutic use, Piperacillin, Tazobactam Drug Combination therapeutic use, Prospective Studies, Antibiotic Prophylaxis, Enterobacteriaceae
- Abstract
Background: This study aimed to evaluate the effectiveness of piperacillin-tazobactam as antibiotic prophylaxis in patients affected by a peri-ampullary tumor submitted to pancreatic surgery. Methods: A prospective, non-randomized, non-blinded, interventional study was conducted from January 2015 to March 2018. Patients were screened pre-operatively for Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBL-PE). During the baseline period (January 2015-October 2016), surgical prophylaxis was performed with ampicillin-sulbactam. In the intervention phase (November 2016-March 2018), patients received piperacillin-tazobactam. Statistical analysis was performed by univariable and multivariable analysis with logistic regression models. Results: Overall, 383 patients were included in the baseline period and 296 in the intervention period. The surveillance strategy identified 47 ESBL-PE carriers (14%) in the baseline phase and 29 (10%) in the intervention phase. In the baseline period, the patients had a higher rate of hospital-acquired infection (43% versus 33%; p = 0.004), superficial surgical site infection (SSI) (11% versus 2%; p < 0.001), and pneumonia (16% versus 9%; p = 0.006). After the logistic regression, the baseline group had an odds ratio to develop superficial SSI and pneumonia of 7.7 (95% confidence interval [CI] 3-20) and 1.8 (95% CI 1-3.3), respectively. The ESBL colonization increased the mortality rate significantly (8% versus 3%; p = 0.017). Conclusions: Adopting antibiotic prophylaxis based on piperacillin-tazobactam is associated with a reduction in post-operative SSI, particularly superficial-SSIs. Further randomized studies would be warranted to evaluate this antibiotic combination more extensively in preventive strategies.
- Published
- 2021
- Full Text
- View/download PDF
22. A Review of Vaccinations in Adult Patients with Secondary Immunodeficiency.
- Author
-
Righi E, Gallo T, Azzini AM, Mazzaferri F, Cordioli M, Merighi M, and Tacconelli E
- Abstract
Vaccine-preventable diseases and their related complications are associated with increased morbidity and mortality in patients with altered immunocompetence. Optimised immunisation in this patient population is challenging because of limited data from vaccine trials, suboptimal vaccine efficacy and safety concerns. Reliable efficacy data are lacking among patients with altered immunocompetence, and existing recommendations are mainly based on expert consensus and may vary geographically. Inactivated vaccines can be generally used without risks in this group, but their efficacy may be reduced, and immunisation schedules vary according to local guidelines, age, and type and stage of the underlying disease. Live vaccines, if indicated, should be administered with care because of the risk of vaccine-associated disease. We have reviewed the current evidence on vaccination principles and recommendations in adult patients with secondary immunodeficiencies, including asplenia, HIV infection, stem cell and solid organ transplant, haematological malignancies, inflammatory bowel disease and other chronic disorders.
- Published
- 2021
- Full Text
- View/download PDF
23. Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg.
- Author
-
Pizzolo F, Rigoni AM, De Marchi S, Friso S, Tinazzi E, Sartori G, Stefanoni F, Nalin F, Montagnana M, Pilotto S, Milella M, Azzini AM, Tacconelli E, Marchi G, Girelli D, Olivieri O, and Martinelli N
- Subjects
- Betacoronavirus, COVID-19, China, Humans, Inpatients, Retrospective Studies, Risk Factors, SARS-CoV-2, Coronavirus Infections, Pandemics, Pneumonia, Viral, Severe acute respiratory syndrome-related coronavirus, Venous Thrombosis etiology
- Published
- 2020
- Full Text
- View/download PDF
24. Personalized machine learning approach to predict candidemia in medical wards.
- Author
-
Ripoli A, Sozio E, Sbrana F, Bertolino G, Pallotto C, Cardinali G, Meini S, Pieralli F, Azzini AM, Concia E, Viaggi B, and Tascini C
- Subjects
- Aged, Aged, 80 and over, Early Diagnosis, Female, Hospitals, Humans, Italy, Male, Middle Aged, Algorithms, Candidemia diagnosis, Diagnostic Techniques and Procedures statistics & numerical data, Machine Learning
- Abstract
Purpose: Candidemia is a highly lethal infection; several scores have been developed to assist the diagnosis process and recently different models have been proposed. Aim of this work was to assess predictive performance of a Random Forest (RF) algorithm for early detection of candidemia in the internal medical wards (IMWs)., Methods: A set of 42 potential predictors was acquired in a sample of 295 patients (male: 142, age: 72 ± 15 years; candidemia: 157/295; bacteremia: 138/295). Using tenfold cross-validation, a RF algorithm was compared with a classic stepwise multivariable logistic regression model; discriminative performance was assessed by C-statistics, sensitivity and specificity, while calibration was evaluated by Hosmer-Lemeshow test., Results: The best tuned RF algorithm demonstrated excellent discrimination (C-statistics = 0.874 ± 0.003, sensitivity = 84.24% ± 0.67%, specificity = 91% ± 2.63%) and calibration (Hosmer-Lemeshow statistics = 12.779 ± 1.369, p = 0.120), markedly greater than the ones guaranteed by the classic stepwise logistic regression (C-statistics = 0.829 ± 0.011, sensitivity = 80.21% ± 1.67%, specificity = 84.81% ± 2.68%; Hosmer-Lemeshow statistics = 38.182 ± 15.983, p < 0.001). In addition, RF suggests a major role of in-hospital antibiotic treatment with microbioma highly impacting antimicrobials (MHIA) that are found as a fundamental risk of candidemia, further enhanced by TPN. When in-hospital MHIA therapy is not performed, PICC is the dominant risk factor for candidemia, again enhanced by TPN. When PICC is not used and MHIA therapy is not performed, the risk of candidemia is minimum, slightly increased by in-hospital antibiotic therapy., Conclusion: RF accurately estimates the risk of candidemia in patients admitted to IMWs. Machine learning technique might help to identify patients at high risk of candidemia, reduce the delay in empirical treatment and improve appropriateness in antifungal prescription.
- Published
- 2020
- Full Text
- View/download PDF
25. A 2020 review on the role of procalcitonin in different clinical settings: an update conducted with the tools of the Evidence Based Laboratory Medicine.
- Author
-
Azzini AM, Dorizzi RM, Sette P, Vecchi M, Coledan I, Righi E, and Tacconelli E
- Abstract
Biomarkers to guide antibiotic treatment decisions have been proposed as an effective way to enhancing a more appropriate use of antibiotics. As a biomarker, procalcitonin (PCT) has been found to have good specificity to distinguish bacterial from non-bacterial inflammations. Decisions regarding antibiotic use in an individual patient are complex and should be based on the pre-test probability for bacterial infection, the severity of presentation and the results of PCT serum concentration. In the context of a high pre-test probability for bacterial infections and/or a high-risk patient with sepsis, monitoring of PCT over time helps to track the resolution of infection and decisions regarding early stop of antibiotic treatment. As outlined by the Evidence Based Laboratory Medicine (EBLM), not only the pre-test probability but also the positive likelihood ratio influence the performance of a test do be really diagnostic. This aspect should be taken into account in the interpretation of the results of clinical trials evaluating the performance of PCT in guiding antibiotic therapy., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-1855). The series “Advances in Laboratory Tests for Infectious Diseases” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare., (2020 Annals of Translational Medicine. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
26. Outbreak of Saprochaete clavata Sepsis in Hematology Patients: Combined Use of MALDI-TOF and Sequencing Strategy to Identify and Correlate the Episodes.
- Author
-
Lo Cascio G, Vincenzi M, Soldani F, De Carolis E, Maccacaro L, Sorrentino A, Nadali G, Cesaro S, Sommavilla M, Niero V, Naso L, Grancini A, Azzini AM, Sanguinetti M, Tacconelli E, and Cornaglia G
- Abstract
Introduction: New fungal species are increasingly reported in immunocompromised patients. Saprochaete clavata ( S. clavata ), an ascomycetous fungus formerly called Geotrichum clavatum , is intrinsically resistant to echinocandins and is often misidentified., Objective: We describe a cluster of seven S. clavata infections in hospitalized hematology patients who developed this rare fungemia within a span of 11 months. Three of the seven patients died. Identification of the isolates was determined only with the Saramis database of VitekMS system and sequencing of the internal transcribed spacer (ITS) region. Clonal relatedness of the isolates was determined by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF) analysis; clonal correlation between the strains was investigated by means of phylogenetic analysis, based on single-nucleotide variants (SNPs). Clinical presentation, 1-3 β-D-glucan (BG) and galactomannan (GM) antigen results and analysis of possible sources of contamination are also described with a prospective case-control study of the outbreak., Results: MALDI-TOF MS-Vitek (bioMerieux, Marcy l'Etoile, France) failed to identify the six isolates, while SARAMIS (bioMerieux, Marcy l'Etoile, France) identified the isolates as S. clavata . Initially, Vitek 2 identified the strains as Geotrichum capitatum in two of the seven cases. Molecular identification gave 99% homology with S. clavata . BG was positive in three out of six patients (range 159 to >523 pg/ml), GM results were always negative. All the isolates were resistant to echinocandins (anidulafungin, micafungin, and caspofungin) and Fluconazole, but susceptible to Flucytosine and Voriconazole. One isolate showed acquired resistance to Flucytosine and Amphotericin B during treatment. Both the correlation-based dendrograms obtained by MALDI-TOF MS (Bruker Daltonics) and MS-Vitek not only clustered six of the seven bloodstream infection (BSI) isolates in the same group, but also showed their strong relatedness. Phylogenetic analysis using SNPrelate showed that the seven samples recorded during the investigation period clustered together. We observed a split between one case and the remainder with a node supported by a z -score of 2.3 ( p -value = 0.021) and 16 mutations unique to each branch., Conclusion: The use of proteomics for identification and evaluation of strain clonality in outbreaks of rare pathogens is a promising alternative to laborious and time-consuming molecular methods, even if molecular whole-genome sequencing (WGS) typing will still remain the reference method for rare emergent pathogens., (Copyright © 2020 Lo Cascio, Vincenzi, Soldani, De Carolis, Maccacaro, Sorrentino, Nadali, Cesaro, Sommavilla, Niero, Naso, Grancini, Azzini, Sanguinetti, Tacconelli and Cornaglia.)
- Published
- 2020
- Full Text
- View/download PDF
27. Clinical Features and Mortality of Nosocomial Candidemia in Very Old Patients: A Multicentre Italian Study.
- Author
-
Zatta M, Di Bella S, Giacobbe DR, Del Puente F, Merelli M, Azzini AM, Brugnaro P, Vedovelli C, Cattelan AM, Busetti M, Gatti G, Bassetti M, and Luzzati R
- Subjects
- Adult, Aged, Aged, 80 and over, Candidemia microbiology, Female, Hospitals statistics & numerical data, Humans, Italy, Male, Middle Aged, Retrospective Studies, Candidemia drug therapy, Candidemia mortality, Cross Infection drug therapy, Cross Infection mortality
- Abstract
Introduction: Being elderly is a well-known risk factor for candidemia, but few data are available on the prognostic impact of candidemia in the very old (VO) subjects, as defined as people aged ≥75 years., Objective: The aim of this study was to assess risk factors for nosocomial candidemia in two groups of candidemia patients, consisting of VO patients (≥75 years) and adult and old (AO) patients (18-74 years). In addition, risk factors for death (30-day mortality) were analysed separately in the two groups., Methods: We included all consecutive candidemia episodes from January 2011 to December 2013 occurring in six referral hospitals in north-eastern Italy., Results: A total of 683 nosocomial candidemia episodes occurred. Of those, 293 (42.9%) episodes were in VO and 390 (57.1%) in AO patients. Hospitalization in medical wards, chronic renal failure, urinary catheter, and peripheral parenteral nutrition (PPN) were more common in VO than in AO patients. In the former patient group, adequate antifungal therapy (73.2%) and central venous catheter (CVC) removal (67.6%) occurred less frequently than in AO patients (82.5 and 80%, p < 0.002 and p < 0.004, respectively). Thirty-day mortality was higher in VO compared to AO patients (47.8 vs. 23.6%, p < 0.0001). In AO patients, independent risk factors for death were age (OR 1.04, 95% CI 1.00-1.09, p = 0.038), recent history of chemotherapy (OR 22.01, 95% CI 3.12-155.20, p = 0.002), and severity of sepsis (OR 40.68, 95% CI 7.42-223.10, p < 0.001); CVC removal was associated with higher probability of survival (OR 0.10, 95% CI 0.03-0.33, p < 0.001). In VO patients, independent risk factors for death were PPN (OR 3.5, 95% CI 1.17-10.47, p = 0.025) and hospitalization in medical wards (OR 2.58, 95% CI 1.02-6.53, p = 0.046), while CVC removal was associated with improved survival (OR 0.40, 95% CI 0.16-1.00, p = 0.050)., Conclusion: Thirty-day mortality was high among VO patients and was associated with inadequate management of candidemia, especially in medical wards., (© 2020 S. Karger AG, Basel.)
- Published
- 2020
- Full Text
- View/download PDF
28. Gross national income and antibiotic resistance in invasive isolates: analysis of the top-ranked antibiotic-resistant bacteria on the 2017 WHO priority list.
- Author
-
Savoldi A, Carrara E, Gladstone BP, Azzini AM, Göpel S, and Tacconelli E
- Subjects
- Anti-Bacterial Agents administration & dosage, Bacteria drug effects, Bacterial Infections drug therapy, Bacterial Infections economics, Humans, Internationality, Poverty, Prevalence, Public Health Surveillance, Socioeconomic Factors, Anti-Bacterial Agents therapeutic use, Bacterial Infections epidemiology, Drug Resistance, Bacterial, Income statistics & numerical data, World Health Organization
- Abstract
Objectives: To assess the association between country income status and national prevalence of invasive infections caused by the top-ranked bacteria on the WHO priority list: carbapenem-resistant (CR) Acinetobacter spp., Klebsiella spp. and Pseudomonas aeruginosa; third-generation cephalosporin-resistant (3GCR) Escherichia coli and Klebsiella spp.; and MRSA and vancomycin-resistant Enterococcus faecium (VR E. faecium)., Methods: Active surveillance systems providing yearly prevalence data from 2012 onwards for the selected bacteria were included. The gross national income (GNI) per capita was used as the indicator for income status of each country and was log transformed to account for non-linearity. The association between antibiotic prevalence data and GNI per capita was investigated individually for each bacterium through linear regression., Results: Surveillance data were available from 67 countries: 38 (57%) were high income, 16 (24%) upper-middle income, 11 (16%) lower-middle income and two (3%) low income countries. The regression showed significant inverse association (P<0.0001) between resistance prevalence of invasive infections and GNI per capita. The highest rate of increase per unit decrease in log GNI per capita was observed in 3GCR Klebsiella spp. (22.5%, 95% CI 18.2%-26.7%), CR Acinetobacter spp. (19.2% 95% CI 11.3%-27.1%) and 3GCR E. coli (15.3%, 95% CI 11.6%-19.1%). The rate of increase per unit decrease in log GNI per capita was lower in MRSA (9.5%, 95% CI 5.2%-13.7%)., Conclusions: The prevalence of invasive infections caused by the WHO top-ranked antibiotic-resistant bacteria is inversely associated with GNI per capita at the global level. Public health interventions designed to limit the burden of antimicrobial resistance should also consider determinants of poverty and inequality, especially in lower-middle income and low income countries., (© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
29. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project.
- Author
-
Bassetti M, Giacobbe DR, Vena A, Trucchi C, Ansaldi F, Antonelli M, Adamkova V, Alicino C, Almyroudi MP, Atchade E, Azzini AM, Carannante N, Carnelutti A, Corcione S, Cortegiani A, Dimopoulos G, Dubler S, García-Garmendia JL, Girardis M, Cornely OA, Ianniruberto S, Kullberg BJ, Lagrou K, Le Bihan C, Luzzati R, Malbrain MLNG, Merelli M, Marques AJ, Martin-Loeches I, Mesini A, Paiva JA, Peghin M, Raineri SM, Rautemaa-Richardson R, Schouten J, Brugnaro P, Spapen H, Tasioudis P, Timsit JF, Tisa V, Tumbarello M, van den Berg CHSB, Veber B, Venditti M, Voiriot G, Wauters J, and Montravers P
- Subjects
- Aged, Candidiasis, Invasive epidemiology, Cross Infection epidemiology, Europe epidemiology, Female, Humans, Incidence, Intensive Care Units organization & administration, Intensive Care Units statistics & numerical data, Male, Middle Aged, Outcome Assessment, Health Care methods, Outcome Assessment, Health Care standards, Outcome Assessment, Health Care statistics & numerical data, Retrospective Studies, Risk Factors, Candidiasis, Invasive complications
- Abstract
Background: The objective of this study was to assess the cumulative incidence of invasive candidiasis (IC) in intensive care units (ICUs) in Europe., Methods: A multinational, multicenter, retrospective study was conducted in 23 ICUs in 9 European countries, representing the first phase of the candidemia/intra-abdominal candidiasis in European ICU project (EUCANDICU)., Results: During the study period, 570 episodes of ICU-acquired IC were observed, with a cumulative incidence of 7.07 episodes per 1000 ICU admissions, with important between-center variability. Separated, non-mutually exclusive cumulative incidences of candidemia and IAC were 5.52 and 1.84 episodes per 1000 ICU admissions, respectively. Crude 30-day mortality was 42%. Age (odds ratio [OR] 1.04 per year, 95% CI 1.02-1.06, p < 0.001), severe hepatic failure (OR 3.25, 95% 1.31-8.08, p 0.011), SOFA score at the onset of IC (OR 1.11 per point, 95% CI 1.04-1.17, p 0.001), and septic shock (OR 2.12, 95% CI 1.24-3.63, p 0.006) were associated with increased 30-day mortality in a secondary, exploratory analysis., Conclusions: The cumulative incidence of IC in 23 European ICUs was 7.07 episodes per 1000 ICU admissions. Future in-depth analyses will allow explaining part of the observed between-center variability, with the ultimate aim of helping to improve local infection control and antifungal stewardship projects and interventions.
- Published
- 2019
- Full Text
- View/download PDF
30. A prediction rule for early recognition of patients with candidemia in Internal Medicine: results from an Italian, multicentric, case-control study.
- Author
-
Sozio E, Pieralli F, Azzini AM, Tintori G, Demma F, Furneri G, Sbrana F, Bertolino G, Fortunato S, Meini S, Bragantini D, Morettini A, Nozzoli C, Menichetti F, Concia E, and Tascini C
- Subjects
- Aged, Aged, 80 and over, Candidemia drug therapy, Case-Control Studies, Cross Infection drug therapy, Early Diagnosis, Female, Humans, Italy epidemiology, Male, Middle Aged, Odds Ratio, Prognosis, Reproducibility of Results, Retrospective Studies, Risk Factors, Sensitivity and Specificity, Severity of Illness Index, Candidemia diagnosis, Candidemia epidemiology, Cross Infection diagnosis, Cross Infection epidemiology, Internal Medicine
- Abstract
Purpose: Increasing prevalence of candidemia in Internal Medicine wards (IMWs) has been reported in recent years, but risk factors for candida bloodstream infection in patients admitted to IMW may differ from those known in other settings. The aim of this study was to identify risk factors and define a prediction rule for the early recognition of the risk of candidemia in IMW inpatients., Methods: This was a multicentric, retrospective, observational case-control study on non-neutropenic patients with candidemia admitted to IMWs of four large Italian Hospitals. Each eligible patient with candidemia (case) was matched to a control with bacteremia. Stepwise logistic regression analyses were performed., Results: Overall, 300 patients (150 cases and 150 controls) were enrolled. The following factors were associated with an increased risk of candidemia and weighted to build a score: total parenteral nutrition (OR 2.45, p = 0.008; 1 point); central venous catheter (OR 2.19, p = 0.031; 1 point); peripherally inserted central catheter (OR 5.63, p < 0.0001; 3 points), antibiotic treatment prior (OR 2.06; p = 0.059; 1 point) and during hospitalization (OR2.38, p = 0.033; 1 point); neurological disability (OR 2.25, p = 0.01; 1 point); and previous hospitalization within 3 months (OR 1.56, p = 0.163; 1 point). At ROC curve analysis, a final score ≥ 4 showed 84% sensitivity, 76% specificity, and 80% accuracy in predicting the risk of candidemia., Conclusions: The proposed scoring system showed to be a simple and highly performing tool in distinguishing bloodstream infections due to Candida and bacteria in patients admitted to IMW. The proposed rule might help to reduce delay in empirical treatment and improve appropriateness in antifungal prescription in septic patients.
- Published
- 2018
- Full Text
- View/download PDF
31. Non-inferiority of open passive drains compared with closed suction drains in pancreatic surgery outcomes: A prospective observational study.
- Author
-
Marchegiani G, Perri G, Pulvirenti A, Sereni E, Azzini AM, Malleo G, Salvia R, and Bassi C
- Subjects
- Aged, Female, Humans, Length of Stay, Male, Middle Aged, Pancreatectomy adverse effects, Pancreatic Diseases complications, Pancreatic Diseases mortality, Pancreatic Diseases surgery, Prospective Studies, Drainage, Pancreatectomy methods, Pancreaticoduodenectomy adverse effects, Pancreaticoduodenectomy methods, Postoperative Complications epidemiology, Suction
- Abstract
Background: Policies concerning the management of operatively placed drains after pancreatic surgery are still under debate. Open passive drains and closed-suction drains are both used currently in clinical practice worldwide, but there are no reliable data regarding potential differences in the postoperative outcomes associated with each drain type. The aim of the present study was to compare open passive drains and closed-suction drains with regard to postoperative contamination of the drainage fluid and overall morbidity and mortality., Methods: This study was a prospective, observational analysis of 320 consecutive, standard, partial resections (pancreaticoduodenectomy and distal pancreatectomy at a single institution from April 2016 to April 2017. Either open passive drains (n = 189, 51%) or closed-suction drains (n = 131) were used according to the operating surgeon's choice. Postoperative outcomes, including samples of drainage fluid collected on postoperative day V and sent for microbiologic analysis, were registered., Results: The open passive drain and closed-suction drain cohorts did not differ in terms of their clinical features, use of neoadjuvant chemotherapy or preoperative biliary drainage, fistula risk zone, and type of operative procedure. The overall rate of postoperative day V drainage fluid contamination (27.5% vs. 20.6%, P = .1) was similar between the groups. The same results were obtained for each specific procedure. The postoperative outcomes, namely, overall 30-day morbidity, postoperative pancreatic fistula, intra-abdominal fluid collections, percutaneous drainage, wound infections, reintervention, mean duration of hospital stay, and mortality did not differ between the 2 groups. Qualitative microbiologic analysis revealed that after pancreaticoduodenectomy, 61.5% of the bacteria contaminating the drainage fluid were attributable to human gut flora, while after distal pancreatectomy, 84.8% of the bacteria belonged to skin and mucous flora (P < .01), however, the spectrum of bacterial contamination did not significantly differ between the open passive drain and closed-suction drain cohorts., Conclusion: The use of open passive drains and closed-suction drains for major pancreatic resection does not significantly impact the postoperative outcome. The spectrum of drain contamination depends on the specific operative procedure rather than on the type of drain used., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
32. Preoperative surveillance rectal swab is associated with an increased risk of infectious complications in pancreaticoduodenectomy and directs antimicrobial prophylaxis: an antibiotic stewardship strategy?
- Author
-
De Pastena M, Paiella S, Azzini AM, Marchegiani G, Malleo G, Ciprani D, Mazzariol A, Secchettin E, Bonamini D, Gasparini C, Concia E, Bassi C, and Salvia R
- Subjects
- Aged, Anti-Bacterial Agents adverse effects, Antibiotic Prophylaxis adverse effects, Antibiotic Prophylaxis mortality, Bacteriological Techniques, Bile microbiology, Databases, Factual, Drainage mortality, Drug Resistance, Multiple, Bacterial, Female, Humans, Male, Middle Aged, Pancreaticoduodenectomy mortality, Retrospective Studies, Risk Assessment, Risk Factors, Surgical Wound Infection diagnosis, Surgical Wound Infection microbiology, Surgical Wound Infection mortality, Treatment Outcome, Anti-Bacterial Agents administration & dosage, Antibiotic Prophylaxis methods, Antimicrobial Stewardship, Drainage adverse effects, Pancreaticoduodenectomy adverse effects, Rectum microbiology, Surgical Wound Infection prevention & control
- Abstract
Background: Despite improvements in the perioperative care, the morbidity rate after pancreaticoduodenectomy (PD) is still higher than 50%. The aim of this study was twofold: first, to assess the correlation between preoperative rectal swab (RS) and intraoperative bile cultures; to examine the impact of RS isolates on postoperative course after PD., Methods: An observational study was conducted analyzing all consecutive PD performed from January 2015 to July 2016. Based on the positivity/negativity of preoperative RS for multi-drug resistant bacteria, two groups of patients were identified (RS+ vs. RS-) and then compared., Results: Three hundred thirty-eight patients were considered for the analysis. RS culture showed a perfect correlation (species and phenotypic antibiotic susceptibility pattern) with bile culture in 157 patients (86.7%). Fifty patients (14.8%) had a RS+. Preoperative biliary drain (PBD) was the single independent preoperative risk factor associated to RS+ (p = 0.021, OR = 2.6, 95% CI = 1.5-11.7). Infective complications (IC) and mortality were independently correlated to RS+ (p = 0.013, OR = 2.9, 95% CI = 1.3-6.7; p = 0.009 OR = 3.4, 95% CI = 1.8-14.9, respectively)., Conclusions: Preoperative surveillance RS-culture's positivity correlates to biliary colonization that occurs after PBD. IC and mortality after PD are associated with RS+. Preoperative RS can direct antibiotic prophylaxis to reduce morbidity and mortality after PD., (Copyright © 2017 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
33. Is there still a role for vancomycin in skin and soft-tissue infections?
- Author
-
Savoldi A, Azzini AM, Baur D, and Tacconelli E
- Subjects
- Anti-Bacterial Agents adverse effects, Drug-Related Side Effects and Adverse Reactions epidemiology, Drug-Related Side Effects and Adverse Reactions pathology, Glycopeptides adverse effects, Glycopeptides therapeutic use, Humans, Linezolid adverse effects, Linezolid therapeutic use, Treatment Outcome, Vancomycin adverse effects, Anti-Bacterial Agents therapeutic use, Drug Utilization, Skin Diseases, Infectious drug therapy, Soft Tissue Infections drug therapy, Vancomycin therapeutic use
- Abstract
Purpose of Review: Skin and soft-tissue infections (SSIs) are among the commonest infections encountered in clinical practice. Spread of methicillin-resistant Staphylococcus aureus SSIs continues to increase in both health care and community settings and presents a challenge for the best treatment choice. Vancomycin has been the mainstay of SSIs treatment, but recently its use has been questioned because of concerns about its efficacy, tolerability, and unfavorable pharmacokinetic/pharmacodynamic profile. The purpose of this review is to establish the current role for vancomycin in light of the literature published from January 2007 to September 2017 on comparison with both old and new alternatives., Recent Findings: Meta-analyses show better clinical and microbiological outcomes for drugs approved for the treatment of SSI, including those sustained by methicillin-resistant S. aureus, in the last 10 years than for vancomycin. The newer glycopeptides and linezolid decrease the total treatment costs compared with vancomycin, by reducing the length of stay or avoiding the hospitalization., Summary: Vancomycin is noninferior in efficacy and safety to all comparator drugs, including the newest on the market. However, the SSI treatment evidence base presents several shortcomings limiting the clinical applicability of the results. High-level clinical trials should be performed to obtain results that can be generalized and applied effectively in clinical practice.
- Published
- 2018
- Full Text
- View/download PDF
34. Nocardia infection over 5 years (2011-2015) in an Italian tertiary care hospital.
- Author
-
Mazzaferri F, Cordioli M, Segato E, Adami I, Maccacaro L, Sette P, Cazzadori A, Concia E, and Azzini AM
- Subjects
- Aged, Aged, 80 and over, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Drug Resistance, Bacterial, Female, Humans, Italy epidemiology, Male, Middle Aged, Nocardia drug effects, Nocardia Infections drug therapy, Retrospective Studies, Tertiary Care Centers, Nocardia isolation & purification, Nocardia Infections epidemiology, Nocardia Infections microbiology
- Abstract
This study was conducted reviewing clinical records of 14 patients affected by nocardiosis over 5 years in a tertiary care hospital. Nocardia abscessus was responsible for one third of infections, deviating significantly from the results reported by other epidemiological investigations and highlighting the key role of molecular identification tests. Indeed, a precise identification of species is crucial for the determination of antibiotic sensitivity patterns and, consequently, for the choice of antibiotic treatment. Noteworthy, 40% of isolates of N. abscessus (formerly N. asteroides complex) showed resistance to carbapenems, which are usually recommended for empirical therapy.
- Published
- 2018
35. Independent risk factors for mortality in critically ill patients with candidemia on Italian Internal Medicine Wards.
- Author
-
Sbrana F, Sozio E, Bassetti M, Ripoli A, Pieralli F, Azzini AM, Morettini A, Nozzoli C, Merelli M, Rizzardo S, Bertolino G, Carrara D, Scarparo C, Concia E, Menichetti F, and Tascini C
- Subjects
- Aged, Aged, 80 and over, Candida drug effects, Candida pathogenicity, Candidemia epidemiology, Chi-Square Distribution, Cohort Studies, Critical Illness epidemiology, Female, Humans, Internal Medicine statistics & numerical data, Internal Medicine trends, Italy epidemiology, Logistic Models, Male, Middle Aged, Multivariate Analysis, Retrospective Studies, Risk Factors, Statistics, Nonparametric, Candidemia mortality, Critical Illness therapy
- Abstract
Candida is an increasing cause of bloodstream infection and is associated with significant morbidity and mortality. The aim of our study is to analyze risk factors for short-term mortality in patients with bloodstream Candida spp. infections admitted to Internal Medicine Wards (IMWs). This was a retrospective case-control study between January 2012 and December 2014 from four University Hospitals in Italy, where patients with candidemia dying within 30 days from diagnosis were matched to control cases with candidemia who survived in the same period of time. Two-hundred and fifty cases of candidemia were registered during the 36 months of enrollment. Among these, 112 patients died (45%) within 30 days from the first blood culture's positivity for Candida spp. At multivariate analysis, septic shock [odds ratio (95% CI) = 2.919 (1.62-5.35), p < 0.001] and concomitant chronic kidney failure [odds ratio (95% CI) = 2.296 (1.07-5.12), p = 0.036] were independent predictors of mortality. Low-dose chronic steroid therapy was protective [odds ratio (95% CI) = 0.461 (0.25-0.83), p = 0.011).
- Published
- 2018
- Full Text
- View/download PDF
36. Klebsiella pneumoniae (ST1519) producing KPC-19 carbapenemase in a patient undergoing selective digestive decontamination before liver transplantation.
- Author
-
Centonze AR, Azzini AM, Mazzi R, Merighi M, Concia E, and Mazzariol A
- Subjects
- Anti-Bacterial Agents pharmacology, Bacterial Proteins drug effects, Bacterial Proteins genetics, Colistin administration & dosage, Gastrointestinal Tract microbiology, Humans, Klebsiella Infections diagnosis, Klebsiella Infections drug therapy, Klebsiella pneumoniae drug effects, Liver Transplantation, Microbial Sensitivity Tests, Middle Aged, beta-Lactamases drug effects, beta-Lactamases genetics, Bacterial Proteins biosynthesis, Klebsiella Infections microbiology, Klebsiella pneumoniae enzymology, Klebsiella pneumoniae isolation & purification, beta-Lactamases biosynthesis
- Published
- 2018
- Full Text
- View/download PDF
37. Performance and operational characteristics of point-of-care tests for the diagnosis of urogenital gonococcal infections.
- Author
-
Guy RJ, Causer LM, Klausner JD, Unemo M, Toskin I, Azzini AM, and Peeling RW
- Subjects
- Humans, Neisseria gonorrhoeae genetics, Sensitivity and Specificity, Chromatography, Affinity methods, DNA, Bacterial analysis, Gonorrhea diagnosis, Gonorrhea microbiology, Neisseria gonorrhoeae isolation & purification, Nucleic Acid Amplification Techniques methods, Point-of-Care Systems
- Abstract
Background: In 2012, there was an estimated 78 million new cases of gonorrhoea globally. Untreated infection may lead to reproductive and neonatal morbidity and facilitate HIV transmission. Diagnosis and treatment are a priority for control and prevention, yet use of point-of-care tests (POCTs) for Neisseria gonorrhoeae (NG) is limited., Objectives: To review the performance and operational characteristics of NG POCTs for diagnosis of urogenital gonorrhoea., Methods: We compiled and synthesised findings from two separate systematic reviews which included evaluations published until August 2015., Results: Six tests were included: five were immunochromatographic tests (ICTs) or optical immunoassay (OIAs) based on antigen detection; with 5-7 steps and results in 25-40 min, and one (GeneXpert CT/NG) was a 'near-patient test' based on nucleic acid amplification technique (NAAT); with three steps, electricity required, and results in 90 min. When compared with laboratory-based NAATs as the reference tests, sensitivities of ICT and OIA-based POCTs ranged from 12.5% to 70% when cervical/vaginal swabs were tested. Specificities ranged from 89% to 99.8%. The near-patient NAAT had sensitivities of >95% and specificities of >99.8% consistently across all specimen types (urine, cervical and vaginal swabs)., Conclusions: Based on a limited number of evaluations, antigen detection POCTs for NG lacked sufficient sensitivity to be used for screening. A near-patient NAAT has acceptable performance, only involved a few steps, but needs electricity, a temperature-controlled environment and has a 90 min run time. To achieve wider scale up of NG POCTs, we need strong evidence of cost-effectiveness, which should inform guidelines and ultimately increase test development, demand and reduce costs., Competing Interests: Competing interests: None declared., (© World Health Organization [2017]. Licensee BMJ Publishing Group Limited. This is an open access article distributed under the terms of the Creative Commons Attribution IGO License(https://creativecommons.org/licenses/by/3.0/igo/), which permits use, distribution, and reproduction for non-commercial purposes in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article’s original URL.)
- Published
- 2017
- Full Text
- View/download PDF
38. Procalcitonin to guide antibiotic stewardship in intensive care.
- Author
-
Dorizzi RM, Azzini AM, and Sette P
- Subjects
- Anti-Bacterial Agents, Biomarkers, Calcitonin Gene-Related Peptide, Critical Care, Humans, Intensive Care Units, Protein Precursors, Antimicrobial Stewardship, Calcitonin
- Published
- 2016
- Full Text
- View/download PDF
39. Disseminated Mycobacterium avium complex disease in a patient with left ventricular assist device (Heart Mate II).
- Author
-
Cordioli M, Del Bravo P, Rigo F, Azzini AM, Merighi M, Forni A, and Concia E
- Subjects
- Antitubercular Agents therapeutic use, Drug Therapy, Combination, Fatal Outcome, Heart Failure, Humans, Immunocompromised Host, Male, Middle Aged, Mycobacterium avium Complex drug effects, Mycobacterium avium-intracellulare Infection drug therapy, Heart-Assist Devices adverse effects, Mycobacterium avium Complex isolation & purification, Mycobacterium avium-intracellulare Infection diagnosis, Mycobacterium avium-intracellulare Infection microbiology
- Abstract
Although disseminated Mycobacterium avium complex disease occurs mainly in immunocompromised hosts, especially HIV-infected patients in the last stage of the disease (AIDS), this condition is still rare in immunocompetent subjects. We report the case of a Caucasian man who received a left ventricular assist device two years before as a bridge to heart transplantation, that began to present signs and symptoms of mycobacterial infection. The diagnostic work-up we performed showed the presence of Mycobacterium intracellulare in lungs and both peripherical and bone marrow blood. Although evaluated, we found no abnormalities in the patient's immune system that can be related to mycobacterial infection. The beginning of a specific therapy made the patient slowly improve and further nuclear medicine assay (PET-TC) showed a good reduction in radio-labelled drug captation.
- Published
- 2015
40. Performance of Alere Determine HIV-1/2 Ag/Ab Combo rapid test for acute HIV infection: a case report.
- Author
-
Lanzafame M, Zorzi A, Rigo F, Adami I, Del Bravo P, Tonolli E, Concia E, and Azzini AM
- Subjects
- Adult, HIV Infections immunology, HIV Infections virology, HIV-1 immunology, HIV-2 immunology, Humans, Immunoassay methods, Male, Predictive Value of Tests, Sensitivity and Specificity, HIV Antibodies blood, HIV Antigens blood, HIV Infections diagnosis, HIV-1 isolation & purification, HIV-2 isolation & purification
- Abstract
We describe a case of symptomatic acute HIV infection in a young man where a fourth-generation rapid screening test combining HIV-specific antibody and p24 antigen was negative. In highly suspicious cases of acute HIV infection, plasma HIV RNA assays together with conventional, non-rapid screening tests should be used.
- Published
- 2015
41. Aetiology and antibiotic resistance issues regarding urological procedures.
- Author
-
Concia E and Azzini AM
- Subjects
- Anti-Bacterial Agents therapeutic use, Humans, Urinary Tract Infections etiology, Antibiotic Prophylaxis methods, Drug Resistance, Microbial physiology, Urinary Tract Infections prevention & control, Urologic Surgical Procedures adverse effects
- Abstract
There are specific indications in urological procedures [transurethral resection of the prostate (TURP), transurethral resection of the bladder (TURB), endoscopic procedures, and all interventions classified as contaminated or dirty] requiring antibiotic prophylaxis. Most postoperative infections are caused by enterococci of the Gram-positive strains and Enterobacteriaceae of the Gram-negative ones. As reported by the European Center for Disease Prevention and Control (ECDC), there are increasing numbers of antibiotic-resistant pathogens. Most Enterococcus faecium strains are ampicillin-resistant and the Enterobacteriaceae have a high prevalence of extended-spectrum beta-lactamase (ESBL) producers, for which the cephalosporins and penicillins are not drugs of choice. In recent years, there are also increasing numbers of Gram-negative strains that are able to produce carbapenemases and for which the only therapeutic options are gentamicin, tigecycline and colistin. An alternative to these drugs, from a prophylactic point of view, is fosfomycin, an old antibiotic that maintains bactericidal activity against both enterococci and multidrug-resistant Enterobacteriaceae. Available in an oral formulation as trometamol salt, fosfomycin reaches high plasma and urine concentrations, and is therefore a possible alternative to other drugs both for therapy and urological prophylaxis.
- Published
- 2014
- Full Text
- View/download PDF
42. Therapeutic recommendations of the multidisciplinary group.
- Author
-
Concia E, Mazzei T, Azzini AM, Diacciati S, Franco M, and Mirone V
- Subjects
- Humans, Urinary Tract Infections etiology, Antibiotic Prophylaxis methods, Practice Guidelines as Topic, Urinary Tract Infections prevention & control, Urologic Surgical Procedures adverse effects
- Published
- 2014
- Full Text
- View/download PDF
43. On the shoulders of giants: a 1500-year-old aphorism.
- Author
-
Dorizzi RM, Sette P, and Azzini AM
- Subjects
- Humans, Atherosclerosis history, Education, Medical standards, Health Knowledge, Attitudes, Practice, Periodicals as Topic
- Published
- 2014
- Full Text
- View/download PDF
44. Preoperative practices overhauled after surgical checklist failure.
- Author
-
Sette P, Dorizzi RM, and Azzini AM
- Subjects
- Hospitals, Urban, Italy, Medical Errors prevention & control, Patient Safety, Surgery Department, Hospital, Checklist, Preoperative Care, Safety Management
- Published
- 2013
45. To see farther standing on the shoulders of Franks and Lieb, who stand on the shoulders of Meyer and Overton, who stand on Bernard's shoulders, who stands...
- Author
-
Sette P, Dorizzi RM, and Azzini AM
- Subjects
- Humans, Biomedical Research history
- Published
- 2013
- Full Text
- View/download PDF
46. Vascular access: an historical perspective from Sir William Harvey to the 1956 Nobel prize to André F. Cournand, Werner Forssmann, and Dickinson W. Richards.
- Author
-
Sette P, Dorizzi RM, and Azzini AM
- Subjects
- Animals, Catheters history, Equipment Design, History, 16th Century, History, 17th Century, History, 18th Century, History, 19th Century, History, 20th Century, Humans, Nobel Prize, Cardiac Catheterization history, Catheterization, Central Venous history, Catheterization, Peripheral history
- Abstract
Sir William Harvey (1578-1657), who had many precursors, discovered blood circulation in 1628 after a significant number of anatomic dissection of cadavers; his studies were continued by Sir Christopher Wren and Daniel Johann Major. The first central vein catheterization was performed on a horse by Stephen Hales, an English Vicar. In 1844, a century later, the French biologist Claude Bernard attempted the first carotid artery cannulation and repeated the procedure in the jugular vein, again on a horse. He was first to report the complications now well known to be associated with this maneuver. In 1929 Werner Forssmann tried cardiac catheterization on himself, but could not investigate the procedure further since his findings were rejected and ridiculed by colleagues. His work was continued by André Frédéric Cournand and Dickinson Woodruff Richards Jr in the United States. In 1956 the three physicians shared the Nobel Prize for Medicine for their studies on vascular and cardiac systems. The genius and the perseverance of the three physicians paved the way towards peripheral and central catheter vein placement, one of the most frequently performed maneuvers in hospitals. Its history still remains unknown to most and deserves a short description.
- Published
- 2012
- Full Text
- View/download PDF
47. Unexpected obstacle in catheter removal could be due to knots spontaneously forming in peripherally inserted central catheters (PICC).
- Author
-
Sette P, Dorizzi RM, and Azzini AM
- Subjects
- Female, Humans, Catheterization, Central Venous instrumentation, Catheters, Indwelling, Electrocardiography instrumentation, Pancreatitis therapy
- Published
- 2011
- Full Text
- View/download PDF
48. First: patient safety, second: patient safety.
- Author
-
Sette P, Dorizzi RM, and Azzini AM
- Subjects
- Humans, Radiography, Interventional, Ultrasonography, Interventional, Catheterization, Central Venous instrumentation, Catheterization, Central Venous methods, Electrocardiography methods, Prosthesis Implantation methods, Safety Management
- Published
- 2011
- Full Text
- View/download PDF
49. Only practice and praxis can limit the unavoidable errors of the practice.
- Author
-
Sette P, Dorizzi R, Azzini AM, and Castellano G
- Subjects
- Catheterization, Central Venous instrumentation, Clinical Competence, Humans, Intensive Care Units, Patient Care Team, Catheterization, Central Venous methods, Medical Staff, Hospital education, Ultrasonography methods
- Published
- 2010
- Full Text
- View/download PDF
50. Serendipitous ECG guided PICC insertion using the guidewire as intra-cardiac electrode.
- Author
-
Sette P, Azzini AM, Dorizzi RM, and Castellano G
- Subjects
- Catheterization, Central Venous methods, Female, Humans, Middle Aged, Ultrasonography, Interventional, Catheterization, Central Venous instrumentation, Catheters, Indwelling, Electrocardiography instrumentation, Pancreatitis therapy
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.